Two of Yazan Al Homsi’s portfolio companies produced independently verifiable news within weeks of each other this year. Rocket Doctor expanded its US reimbursement footprint through a five-channel California network agreement announced August 18, and Aduro Clean Technologies selected the engineering group Saipem for preliminary work on its planned Chemelot recycling facility — two very different industries, evaluated through the same investor lens.
Neither event, on its own, settles whether either company reaches the scale that attracts institutional capital. Taken together, they offer a window into what the Vancouver-based investor actually treats as evidence: not a headline number or an announcement date, but whether the next gate in each project — credentialing and claims volume for Rocket Doctor, a credible capital cost estimate for Aduro — gets cleared. That is a higher bar than most press coverage of either announcement applied.
Al Homsi holds disclosed equity positions in both companies through Founders Round Capital and has no board seat or operating role at either. His broader framework for weighing early-stage evidence across a portfolio is outlined on his website, and his professional history is listed on LinkedIn. He treats the two stories as related tests of the same underlying question: does the announcement change what the company can execute, or only what it can say.
For Rocket Doctor specifically, that means the August network deal is one data point in a longer chain — useful mainly for what it enables next, rather than as a standalone proof of scale.